MCID: PMP005
MIFTS: 58

Pemphigus Vulgaris

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Pemphigus Vulgaris

MalaCards integrated aliases for Pemphigus Vulgaris:

Name: Pemphigus Vulgaris 39 12 77 54 56 15 17 74
Pemphigus Vulgaris, Familial 74
Familial Pemphigus Vulgaris 12
Pemphigus 45

Classifications:



Summaries for Pemphigus Vulgaris

NIH Rare Diseases : 54 Pemphigus vulgaris is an autoimmune disorder that involves blistering and erosion of the skin and mucous membranes. It occurs almost exclusively in middle-aged or older people. The primary lesion of pemphigus vulgaris is a soft blister filled with clear fluid that appears on healthy or irritated skin. Many cases begin with blisters in the mouth, followed by skin blisters that may come and go. The blisters inside the mouth can make it hard for the person to eat. The rupture of blisters on the skin may be painful and limit the person's daily activities. Complications due to infections can be serious and the damaging nature of the blisters can cause loss of body fluids and protein. The exact cause of pemphigus vulgaris is unknown, but the blisters in pemphigus vulgaris are associated with the binding of antibodies to the skin cells. Treatment is aimed at reducing symptoms and preventing complications, and may include the use of corticosteroids, immunosuppressive drugs, and more recently immunotherapy. Pemphigus vulgaris may require long term treatment to keep it in remission.

MalaCards based summary : Pemphigus Vulgaris, also known as pemphigus vulgaris, familial, is related to ritter's disease and pemphigus vegetans. An important gene associated with Pemphigus Vulgaris is DSG3 (Desmoglein 3), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Triamcinolone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and cervix, and related phenotypes are feeding difficulties in infancy and abnormal blistering of the skin

Disease Ontology : 12 A pemphigus characterized by autosomal dominant blisters and erosions on the skin and mucous membranes erosions cause by autoantibodies to intercellular cement substance.

Wikipedia : 77 Pemphigus (/ˈpɛmfɪɡəs/ or /pɛmˈfaɪɡəs/) is a rare group of blistering autoimmune diseases that affect... more...

Related Diseases for Pemphigus Vulgaris

Diseases in the Pemphigus Vulgaris family:

Pemphigus Vulgaris, Familial

Diseases related to Pemphigus Vulgaris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 371)
# Related Disease Score Top Affiliating Genes
1 ritter's disease 32.9 DSG1 DSG2 DSG4
2 pemphigus vegetans 32.6 DSC3 DSG1 PPL
3 epidermolysis bullosa, lethal acantholytic 32.0 DSP JUP
4 subcorneal pustular dermatosis 31.1 DSC3 DSG1 DSG3 DST EVPL PPL
5 pemphigus erythematosus 31.0 DSG3 DSP
6 pemphigus 30.7 DSC3 DSG1 DSG2 DSG3 DSG4 DSP
7 autoimmune disease 30.5 DSG1 HLA-DRB1 TNFSF13B
8 bullous impetigo 30.5 DSG1 DSG3
9 follicular dendritic cell sarcoma 30.4 DSP EVPL PPL
10 grover's disease 30.2 DSP JUP
11 darier-white disease 30.1 DSP JUP
12 benign chronic pemphigus 30.1 DSP JUP
13 pemphigoid gestationis 30.0 DST HLA-DRB1
14 hypotrichosis 29.9 DSC3 DSG1 DSG4
15 pemphigus foliaceus 29.9 DSG1 DSG2 DSG3 DST EVPL HLA-DRB1
16 herpetiform pemphigus 29.7 DSG1 DSG3 DST
17 bullous pemphigoid 29.3 DSG1 DSG3 DSP DST EVPL HLA-DRB1
18 skin disease 28.8 DSC3 DSG1 DSG3 DSG4 DSP DST
19 cellulitis 28.7 DSC3 DSG1 DSG3 DSP DST PPL
20 paraneoplastic pemphigus 28.5 DSC3 DSG1 DSG2 DSG3 DSP DST
21 bullous skin disease 28.0 DSC3 DSG1 DSG3 DSP DST EVPL
22 pemphigus vulgaris, familial 13.0
23 pemphigus and fogo selvagem 12.4
24 brunsting-perry syndrome 11.0
25 recessive dystrophic epidermolysis bullosa-generalized other 11.0
26 linear iga disease 10.7
27 herpes simplex 10.5
28 lupus erythematosus 10.4
29 lichen planus 10.4
30 systemic lupus erythematosus 10.3
31 myasthenia gravis 10.3
32 arthritis 10.3
33 squamous cell carcinoma 10.3
34 dermatitis 10.3
35 myasthenia gravis congenital 10.3
36 sarcoma 10.3
37 esophagitis 10.3
38 erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper-ige 10.3 DSG1 DSP
39 rheumatoid arthritis 10.3
40 paronychia 10.3
41 psoriasis 10.3
42 palmoplantar keratoderma and woolly hair 10.3 DSP JUP
43 polycythemia vera 10.2
44 dermatitis herpetiformis, familial 10.2
45 colitis 10.2
46 dermatitis herpetiformis 10.2
47 distal trisomy 3p 10.2
48 naxos disease 10.2 DSP JUP
49 ectodermal dysplasia/skin fragility syndrome 10.2 DSP JUP
50 leukemia 10.2

Graphical network of the top 20 diseases related to Pemphigus Vulgaris:



Diseases related to Pemphigus Vulgaris

Symptoms & Phenotypes for Pemphigus Vulgaris

Human phenotypes related to Pemphigus Vulgaris:

33 (show all 9)
# Description HPO Frequency HPO Source Accession
1 feeding difficulties in infancy 33 hallmark (90%) HP:0008872
2 abnormal blistering of the skin 33 hallmark (90%) HP:0008066
3 weight loss 33 hallmark (90%) HP:0001824
4 atypical scarring of skin 33 hallmark (90%) HP:0000987
5 autoimmunity 33 hallmark (90%) HP:0002960
6 recurrent cutaneous abscess formation 33 hallmark (90%) HP:0100838
7 urticaria 33 hallmark (90%) HP:0001025
8 acantholysis 33 hallmark (90%) HP:0100792
9 abnormal oral cavity morphology 33 hallmark (90%) HP:0000163

MGI Mouse Phenotypes related to Pemphigus Vulgaris:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.23 CDH1 DSC3 DSG1 DSG3 DSG4 DSP

Drugs & Therapeutics for Pemphigus Vulgaris

Drugs for Pemphigus Vulgaris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
2
Mycophenolic acid Approved Phase 3 24280-93-1 446541
3
ofatumumab Approved Phase 3 679818-59-8 6918251
4
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
5
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
6
Prednisone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 53-03-2 5865
7
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
8
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
9
rituximab Approved Phase 3 174722-31-7 10201696
10
Acetaminophen Approved Phase 3 103-90-2 1983
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Cetirizine Approved Phase 3 83881-51-0 2678
13
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
14 Triamcinolone hexacetonide Phase 3
15 Anti-Inflammatory Agents Phase 3,Phase 2
16 Hormones Phase 3,Phase 2
17 Immunosuppressive Agents Phase 3,Phase 2,Early Phase 1
18 Hormone Antagonists Phase 3,Phase 2
19 Immunologic Factors Phase 3,Phase 2,Early Phase 1
20 Triamcinolone diacetate Phase 3
21 triamcinolone acetonide Phase 3
22 glucocorticoids Phase 3,Phase 2
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
24 Antibiotics, Antitubercular Phase 3,Early Phase 1
25 Antitubercular Agents Phase 3
26 Anti-Infective Agents Phase 3,Phase 2,Early Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Early Phase 1
28 Immunoglobulins Phase 3,Phase 2
29 Antibodies, Monoclonal Phase 3,Phase 2
30 Antibodies Phase 3,Phase 2
31 Antirheumatic Agents Phase 3,Phase 2
32 Prednisolone acetate Phase 3,Phase 2
33 Peripheral Nervous System Agents Phase 3,Phase 2
34 Gastrointestinal Agents Phase 3,Phase 2
35 Analgesics, Non-Narcotic Phase 3,Phase 2
36 Antineoplastic Agents, Hormonal Phase 3,Phase 2
37 Methylprednisolone Acetate Phase 3,Phase 2
38 Analgesics Phase 3,Phase 2
39 tyrosine Phase 3
40 Antineoplastic Agents, Immunological Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Anti-Allergic Agents Phase 3
43 Autonomic Agents Phase 3
44 Histamine H1 Antagonists Phase 3
45 Antipyretics Phase 3
46 Neurotransmitter Agents Phase 3
47 Histamine Antagonists Phase 3
48 Protective Agents Phase 3
49 Histamine H1 Antagonists, Non-Sedating Phase 3
50 Neuroprotective Agents Phase 3

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris Completed NCT02828163 Phase 3 Triamcinolone Acetonide
2 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Completed NCT00683930 Phase 3 Mycophenolate Mofetil 2 g/Day;Mycophenolate Mofetil (MMF) 3 g/Day;Placebo
3 Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris Completed NCT01920477 Phase 3
4 A Study of PRN1008 in Patients With Pemphigus Recruiting NCT03762265 Phase 3 PRN1008 Oral Tablet;Placebo Oral Tablet
5 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Active, not recruiting NCT02383589 Phase 3 Mycophenolate Mofetil Placebo;Mycophenolate Mofetil;Rituximab;Rituximab Placebo
6 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
7 Use of KC706 for the Treatment of Pemphigus Vulgaris Completed NCT00606749 Phase 2 KC706
8 Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone Completed NCT00626678 Phase 2 Azathioprine;Prednisone;Placebo
9 Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris Completed NCT00135720 Phase 2 Enbrel (Etanercept)
10 Use of Infliximab for the Treatment of Pemphigus Vulgaris Completed NCT00283712 Phase 2 Infliximab
11 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris Recruiting NCT02704429 Phase 2 PRN1008
12 A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus Recruiting NCT03334058 Phase 2 ARGX-113
13 A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Recruiting NCT03075904 Phase 1, Phase 2 SYNT001
14 Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris Active, not recruiting NCT01930175 Phase 2 VAY736;Placebo to VAY736;VAY736
15 A Study of the Safety and Tolerability of Parsaclisib in Pemphigus Vulgaris Not yet recruiting NCT03780166 Phase 2 Parsaclisib
16 Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Terminated NCT00429533 Phase 2 Dapsone
17 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus Terminated NCT00483119 Phase 2 intravenous immunoglobulin;cyclophosphamide
18 Safety Study of PI-0824 to Treat Pemphigus Vulgaris Completed NCT00063752 Phase 1 PI-0824
19 Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus Recruiting NCT03239470 Phase 1
20 Autoimmune Blistering Diseases Study Unknown status NCT02753777
21 Serum IL-21 Levels in Patients With Pemphigus Vulgaris Not yet recruiting NCT03177213
22 Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus Terminated NCT01313923 Early Phase 1 Sirolimus (formerly known as Rapamycin)

Search NIH Clinical Center for Pemphigus Vulgaris

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pemphigus Vulgaris cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pemphigus Vulgaris:
Hematopoietic stem cells for pemphigus

Cochrane evidence based reviews: pemphigus

Genetic Tests for Pemphigus Vulgaris

Anatomical Context for Pemphigus Vulgaris

MalaCards organs/tissues related to Pemphigus Vulgaris:

42
Skin, T Cells, Cervix, B Cells, Testes, Thyroid, Lung

Publications for Pemphigus Vulgaris

Articles related to Pemphigus Vulgaris:

(show top 50) (show all 1889)
# Title Authors Year
1
Infective endocarditis in two patients with pemphigus vulgaris under multiagent immunosuppressive drug therapy: a rare entity to remember in the differential diagnosis of fever of unknown origin. ( 30758911 )
2019
2
Etanercept for pemphigus vulgaris. ( 30636400 )
2019
3
Hailey-Hailey-Like Pattern of Acantholysis on the Scalp Should Raise the Possibility of Incipient Pemphigus Vulgaris. ( 30640761 )
2019
4
"Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran": A multiple cross-sectional study. ( 30659718 )
2019
5
"IgG/IgA Pemphigus in a Patient with a History of Pemphigus Vulgaris: An Example of Epitope Spreading? ( 30681733 )
2019
6
Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris. ( 30692201 )
2019
7
Decrease of Anti-DSG3, But Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris. ( 30698623 )
2019
8
Koebner phenomenon: pemphigus vulgaris following Mohs micrographic surgery. ( 30710902 )
2019
9
Improving Treatment Outcome of Pemphigus Vulgaris on Vietnamese Patients by Using Desmoglein Elisa Test. ( 30745956 )
2019
10
Long-term evaluation of pemphigus vulgaris: a retrospective consideration of 98 patients treated in an oral medicine unit in North-West Italy. ( 30860627 )
2019
11
Beware of anal fissures: pemphigus vulgaris of the anal canal. ( 30872911 )
2019
12
Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases. ( 30877872 )
2019
13
The use of BIOCHIP technique in diagnosis of different types of pemphigus: Vulgaris and foliaceus. ( 30910537 )
2019
14
Trace element profile in pemphigus foliaceus and in pemphigus vulgaris patients from Southeastern Brazil. ( 30466935 )
2019
15
Pemphigus Vulgaris. ( 30503724 )
2019
16
New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature. ( 29872685 )
2018
17
A case of antiepiligrin cicatricial pemphigoid with extensive cutaneous erosions mimicking pemphigus vulgaris. ( 29930192 )
2018
18
Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy. ( 29689136 )
2018
19
Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission. ( 29609015 )
2018
20
An Oral Disease Severity Score (ODSS) validated for use in oral pemphigus vulgaris. ( 29297927 )
2018
21
Validity of the EQ-5D in pemphigus vulgaris and foliaceus patients. ( 29897626 )
2018
22
Keratin Retraction and Desmoglein3 Internalization Independently Contribute to Autoantibody-Induced Cell Dissociation in Pemphigus Vulgaris. ( 29922278 )
2018
23
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. ( 29848521 )
2018
24
Pemphigus Vulgaris and Radiotherapy. ( 29097073 )
2018
25
Auftreten einer Psoriasis vulgaris bei einem Patienten mit Pemphigus vulgaris unter Kortikosteroidtherapie. ( 29750447 )
2018
26
A Case of Concomitant Pemphigus Foliaceus and Oral Pemphigus Vulgaris. ( 29340948 )
2018
27
Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris. ( 29489039 )
2018
28
A case of pemphigus vulgaris associated with ulcerative colitis. ( 29422810 )
2018
29
Increased expression of microRNA-338-3p contributes to production of Dsg3 antibody in pemphigus vulgaris patients. ( 29749496 )
2018
30
Study of Extrinsic Apoptotic Pathway in Oral Pemphigus Vulgaris Using TNFR 1 and FasL Immunohistochemical Markers and TUNEL Technique. ( 29854887 )
2018
31
Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris. ( 29915578 )
2018
32
Tracing the origins of active amide group-positive drug-induced pemphigus vulgaris along the Silk Road: a case report of candesartan-induced pemphigus vulgaris and review of nonthiol drug-induced pemphigus. ( 29974942 )
2018
33
Immunological markers as predictors of developing steroid-induced diabetes mellitus in pemphigus vulgaris patients: An observational study. ( 29702999 )
2018
34
Incidence of pemphigus vulgaris and pemphigus foliaceus in North-East Poland (Podlaskie Province) - a 15-year (2001-2015) bicentric retrospective study. ( 29873080 )
2018
35
Contact allergy caused by methylisothiazolinone in a mouthwash as the likely trigger of oral pemphigus vulgaris. ( 29726598 )
2018
36
Anti-Thyroid Peroxidase Reactivity Is Heightened in Pemphigus Vulgaris and Is Driven by Human Leukocyte Antigen Status and the Absence of Desmoglein Reactivity. ( 29675021 )
2018
37
Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. ( 29110080 )
2018
38
Association between human leukocyte antigen-DRB1 and human leukocyte antigen-DQB1 alleles and pemphigus vulgaris in Indian patients: A case-control study. ( 29582787 )
2018
39
Emerging treatment options for the management of pemphigus vulgaris. ( 29740210 )
2018
40
Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. ( 29132070 )
2018
41
Association study and fine-mapping major histocompatibility complex analysis of pemphigus vulgaris in a Han Chinese population. ( 29857070 )
2018
42
Autoantibody Signaling in Pemphigus Vulgaris: Development of an Integrated Model. ( 29755451 )
2018
43
Association between HLA-DQB1 polymorphisms and pemphigus vulgaris: A meta-analysis. ( 29182409 )
2018
44
Risk of Atrial Fibrillation in Pemphigus Vulgaris. ( 30050823 )
2018
45
Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris. ( 30157430 )
2018
46
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 30521827 )
2018
47
Coexistence of oral lichen planus and pemphigus vulgaris. ( 30218230 )
2018
48
The impact of human herpesvirus detection in pemphigus vulgaris. ( 30537024 )
2018
49
Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris. ( 30567283 )
2018
50
Successful Treatment of Pemphigus Vulgaris With Ofatumumab ( 30586270 )
2018

Variations for Pemphigus Vulgaris

Expression for Pemphigus Vulgaris

Search GEO for disease gene expression data for Pemphigus Vulgaris.

Pathways for Pemphigus Vulgaris

GO Terms for Pemphigus Vulgaris

Cellular components related to Pemphigus Vulgaris according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.9 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
2 intermediate filament GO:0005882 9.8 DSP DST EVPL JUP PPL
3 cell-cell junction GO:0005911 9.72 DSC3 DSG1 DSG2 DSP JUP
4 lateral plasma membrane GO:0016328 9.67 CDH1 DSG1 DSG2 JUP
5 cytoplasmic side of plasma membrane GO:0009898 9.65 CDH1 DSG1 JUP
6 intercalated disc GO:0014704 9.63 DSG2 DSP JUP
7 cornified envelope GO:0001533 9.61 DSC3 DSG1 DSG2 DSG3 DSG4 DSP
8 catenin complex GO:0016342 9.56 CDH1 JUP
9 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.55 HLA-DRB1 HLA-G
10 fascia adherens GO:0005916 9.52 DSP JUP
11 hemidesmosome GO:0030056 9.51 DST JUP
12 desmosome GO:0030057 9.28 DSC3 DSG1 DSG2 DSG3 DSG4 DSP
13 membrane GO:0016020 10.28 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
14 integral component of membrane GO:0016021 10.24 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
15 extracellular exosome GO:0070062 10.1 CDH1 DSG2 DSG3 DSP EVPL HLA-DRB1
16 plasma membrane GO:0005886 10.07 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4

Biological processes related to Pemphigus Vulgaris according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.86 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
2 cell-cell adhesion GO:0098609 9.8 CDH1 DSG1 DSG4 DSP JUP
3 wound healing GO:0042060 9.76 DSP DST EVPL PPL
4 keratinocyte differentiation GO:0030216 9.71 DSG4 DSP EVPL
5 adherens junction organization GO:0034332 9.67 CDH1 DSP JUP
6 regulation of heart rate by cardiac conduction GO:0086091 9.65 DSG2 DSP JUP
7 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.63 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
8 intermediate filament cytoskeleton organization GO:0045104 9.62 DSP DST EVPL PPL
9 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.61 DSG2 DSP JUP
10 keratinization GO:0031424 9.61 DSC3 DSG1 DSG2 DSG3 DSG4 DSP
11 response to progesterone GO:0032570 9.57 DSG1 DSG2
12 positive regulation of protein import into nucleus GO:0042307 9.56 CDH1 JUP
13 maternal process involved in female pregnancy GO:0060135 9.55 DSG1 DSG2
14 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.54 DSG2 DSP JUP
15 cellular response to indole-3-methanol GO:0071681 9.52 CDH1 JUP
16 desmosome organization GO:0002934 9.51 DSG2 DSP
17 cornification GO:0070268 9.28 DSC3 DSG1 DSG2 DSG3 DSG4 DSP

Molecular functions related to Pemphigus Vulgaris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.7 CDH1 DSC3 DSG1 DSG2 DSG3 DSG4
2 structural molecule activity GO:0005198 9.65 DSP DST EVPL JUP PPL
3 cadherin binding GO:0045296 9.62 CDH1 EVPL JUP PPL
4 peptide antigen binding GO:0042605 9.4 HLA-DRB1 HLA-G
5 gamma-catenin binding GO:0045295 9.37 CDH1 DSG1
6 cell adhesion molecule binding GO:0050839 9.26 CDH1 DSG2 DSP JUP
7 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.8 DSG2 DSP JUP

Sources for Pemphigus Vulgaris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....